Collaborative Protein Target Screening RFA – Due Jan. 11, 2019

The Dan L Duncan Comprehensive Cancer Center (DLDCCC) and Center for Drug Discovery (CDD) are collaborating to fund up to nine - $7,000 pilot projects to be awarded before Jan. 30, 2019. We are seeking “validated” and potentially “druggable” cancer targets and will support screening them using the CDD’s DNA-Encoded Chemistry Technology (DEC-Tec).

Applicants should discuss the feasibility of their project with Dr. Martin Matzuk (mmatzuk@bcm.edu) and his CDD team before submitting an application to ensure that the target protein is a potential candidate and the proposed screen is feasible. Applicant teams will need to supply His-tagged recombinant target protein, while the CDD will perform a multi-BILLION compound screen of their available DNA-encoded chemical libraries and supply hits for follow-up validation assays in the applicant’s laboratory.

The final one-page application should focus on the rationale for choosing the target protein and the experimental plan including the DEC-Tec screening, the available follow-up target validation assays, and future development of lead compounds. Please email the final applications after discussions with Dr. Matzuk to Danielle Gilmore Danielle.Gilmore@bcm.edu.

Deadline for application: Friday – Jan. 11. 

FNIH PACT Issues RFA for Novel Biomarker Development in Cancer Immunoprofiling

The FNIH is issuing a Request for Applications (RFA) for novel biomarkers to support the Partnership for Accelerating Cancer Therapies (PACT), a project associated with the Beau Biden Cancer Moonshot™ Initiative.

The mission of PACT is to facilitate robust, systematic, and uniformly conducted clinical testing of biomarkers that enable researchers and clinicians to better understand the mechanisms of response and resistance to cancer immunotherapy treatment strategies. To enable this mission, PACT is working with the National Cancer Institute’s Cancer Immune Monitoring and Analysis Centers and the Cancer Immunologic Data Commons (NCI CIMAC-CIDC) Network to provide a systematic approach to immune and related oncology biomarker investigation in clinical trials by providing standardized and harmonized biomarker assays.

In addition to refining existing assays for broader use, PACT seeks to further the development of novel exploratory biomarker assays, which can be utilized within PACT and across the research community.  To encourage development of novel cutting-edge immunoprofiling assays for eventual clinical deployment, PACT is launching this specific RFA to solicit proposals to assist in driving promising novel biomarkers and assays toward analytical and clinical validation and eventually regulatory approval. This specific RFA is targeted to very focused areas within the fields of liquid biopsy, tumor microenvironment, and the microbiome that can assist clinicians in accurately predicting response to immuno-oncology interventions.

Key Dates

Application Due Date: Jan. 21, 2019, 11:59 p.m. EST

Targeted Application Review Period: Jan. 22, 2019 – Feb. 22, 2019

Potential Oral Presentations from Finalists (If Needed): Feb. 25-28, 2019

Applicants will be informed after initial review of proposals whether they will need to provide and oral presentation with the ability for Q&A to the PACT RFA Review Team

Targeted Award Announcement: March 2019

Applicants will be notified by email of the outcome of the RFA.

For more information please visit: www.fnih.org/PACT or contact PACT@fnih.org.

PACT is executed by FNIH as a public-private partnership involving the National Cancer Institute (NCI), the U.S. Food and Drug Administration (FDA), multiple pharmaceutical companies, academic institutions, non-profits and patient advocates.

 

NIH Grant Funding Opportunities

Current NIH funding opportunity announcements:

American Cancer Society Research Grants

The American Cancer Society awards research grants and fellowships to promising early-career scientists with unique hypotheses for cancer prevention and study, fostering the next generation of cancer research and creating a strong foundation of preliminary evidence to make scientific advancements. We also sponsor grants in support of training for health professionals seeking to develop their clinical expertise and/or their ability to conduct independent research.